Amneal Reports Third Quarter 2026 Financial Results
Globe Newswire•03/11/2026•06:00 ET
0
Key Highlights
- ➤Q3 net revenue $863 million, up 10% year over year
- ➤Q3 GAAP net loss $22 million versus $2 million net income
- ➤Adjusted EBITDA $207 million, up 30% year over year
- ➤2026 adjusted EBITDA guidance raised to $800 million-$815 million from $750 million-$780 million
- ➤2026 operating cash flow guidance lowered to $325 million-$375 million from $350 million-$400 million
Expert Statements
Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal
“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT(®), and BREKIYA(®) autoinjector. The Kashiv integration is proceeding well, and we are excited about the long-term growth potential in biosimilars. With the breadth and depth of opportunities across our portfolio, we remain highly confident in Amneal’s robust growth outlook”
– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance –
BRIDGEWATER, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.